*Actual product packaging may differ from the image shown.
Wegovy® (Injectable, Brand Name)
Depending on the dose prescribed
$396.00–$621.00
Shop All Treatments
Wegovy (Semaglutide): FDA-Approved Weekly Injection for Weight Loss
The only FDA-approved semaglutide product indicated specifically for weight management.
Wegovy is an FDA-approved injectable containing semaglutide, taken once weekly and specifically indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It contains the same molecule as Ozempic but at a higher therapeutic dose (2.4 mg) studied specifically for weight loss. Wegovy is also approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity.
FDA-approved for weight loss · Physician-prescribed · Manufactured by Novo Nordisk · Ongoing care team support
Semaglutide 2.4 mg (GLP-1 Receptor Agonist): Wegovy activates GLP-1 receptors in your brain and gut, reducing appetite, slowing stomach emptying, and producing the satiety signal that lets smaller portions feel like enough. At 2.4 mg weekly, the dose studied in the STEP trials, semaglutide produces the largest weight loss documented for a GLP-1 monotherapy. Your dose is increased gradually over four months, which is the standard way to minimize digestive side effects.
Best for: Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as hypertension, type 2 diabetes, or sleep apnea. Particularly well-suited for people who want the FDA-approved version of semaglutide specifically studied for weight loss.
Not recommended for: Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, those with a history of pancreatitis, anyone pregnant or breastfeeding, and anyone already taking another GLP-1 medication.
The most common side effects are nausea, diarrhea, constipation, vomiting, and stomach pain, particularly during the first weeks and dose increases. These usually improve as your body adjusts. Rare but serious risks include pancreatitis, gallbladder disease, kidney problems related to dehydration, and (based on animal data) a theoretical risk of medullary thyroid tumors. Wegovy carries a boxed warning for medullary thyroid carcinoma risk.
¹ 86% of patients lost at least 5% of body weight Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). NEJM, 2021;384(11):989-1002. (86.4% achieved ≥5% vs 31.5% placebo.) → NEJM · PubMed
² 50% lost at least 15% of body weight (average loss ~15%) Wilding JPH, et al. STEP 1 (same source as ¹). (50.5% achieved ≥15%; mean -14.9% vs -2.4% placebo.) → NEJM · PubMed
³ 20% lower risk of heart attack, stroke, and cardiovascular death Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). NEJM, 2023;389(24):2221-2232. (20% MACE reduction; HR 0.80.) → NEJM · PubMed
Mechanism reference (not a numbered efficacy claim): Drucker DJ. Cell Metabolism, 2018;27(4):740-756. → PubMed
How it Works With EHRX
The entire process is online. No waiting rooms. Just straightforward, medically guided care.
Step 1
Choose your treatment and complete checkout
You'll receive a confirmation email with next steps.
Step 2
Complete a brief medical consultation
Check your email for a link to a short intake form and link to a virtual consult with a licensed physician.
Step 3
A licensed provider reviews your consultation
If approved, your prescription is written and sent to the pharmacy. If not, you receive a full refund.
Step 4
Your pharmacy ships within 3–5 business days
Your medication is shipped directly to your door in temperature-controlled packaging.
What to know before you start.
Wegovy® (Injectable, Brand Name) is a compounded medication prepared by a licensed pharmacy for individual patient use.
It has not been reviewed by the FDA for safety or efficacy, and is prescribed based on the clinical judgment of a qualified healthcare provider. Compounded drugs are permitted to be prescribed but are not FDA-approved for safety and efficacy.
Clinical Evidence
In the STEP 1 trial, adults with obesity taking once-weekly semaglutide 2.4 mg (Wegovy) for 68 weeks lost an average of 14.9% of their body weight versus 2.4% with placebo. 86% of participants achieved at least 5% weight loss. In the SELECT trial, Wegovy also reduced the risk of major cardiovascular events by 20% in adults with established cardiovascular disease and obesity. (Source: Wilding et al., NEJM, 2021; Lincoff et al., NEJM, 2023)
Frequently Asked Questions
We aim to provide absolute clarity regarding your biological data and personalized wellness protocols.
Same molecule. Wegovy is dosed at 2.4 mg weekly and is FDA-approved specifically for chronic weight management. Ozempic is dosed up to 2 mg weekly and is approved for type 2 diabetes.
Once weekly via a pre-filled auto-injector pen, in your abdomen, thigh, or upper arm.
Reduced appetite usually begins within the first one to two weeks. Visible weight loss starts by week 4, with continued progress through 12 to 18 months.
Wegovy is approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition.
A baseline metabolic panel is recommended in most cases.
You won’t be charged for the medication.
Coverage varies by plan. Some insurers cover Wegovy for qualifying patients; others don’t cover weight-loss medications. Your provider’s team can help you understand your options.
Yes, at any time before your next shipment, with no long-term commitment.
Monthly during titration, then on a recurring cadence as you stabilize.
Most digestive symptoms improve within weeks or with a slower titration. Contact your care team for anything persistent.
Weight regain is common when GLP-1 medications are stopped. Your provider will discuss long-term protocol options.
The next generation
of weight management.
Dual-incretin metabolic support — personalized to you.
